Bydureon - Here is the truth

Discussion in 'Amylin' started by Anonymous, Jan 27, 2012 at 5:26 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    It will keep you employed. It will not be a blockbuster, but it will keep you employed. It will be a 500 million drug in the future. It will keep Amylin going for a while, and it saved jobs. Congrats. Now, get out there and find the select people that can handle the complex delivery system. It won't be easy, but there will be a place.
     

  2. Anonymous

    Anonymous Guest

    The delivery system is really easy actually... Nice try though.

    Stop believing the Novo scare tactics.
     
  3. Anonymous

    Anonymous Guest

    you all are fags
     
  4. Anonymous

    Anonymous Guest

    Analysts generally expect Bydureon to generate $940 million in sales annually by 2016, though Deutsche Bank analyst Robyn Karnauskas says the drug must post $1.2 billion annually to turn a profit.

    Karnauskas points out in a note to investors that Amylin currently has $2 billion in long-term debt and only $210 million in cash
     
  5. Anonymous

    Anonymous Guest

    Let's see. Google the recent news on Bydureon.
    *Projected to be as high as $2Billion by the end of the decade, even with all the new entries to come into the diabetes market.
    *Listed as the 1st of the top 15 blockbuster drugs to get FDA approval in the near future
    *Expected that patients will prefer the convenience of fewer shots
    *As for pricing, Forbes says Bydureon will cost about $4,200, compared with roughly $5,000 for high-dosage Victoza.
    * Meanwhile, Novo Nordisk was trying to position itself by signing Paula Deen, the self-styled ‘Queen of Southern Cuisine’ and Food Network star, as a spokesperson. However, Deen knew she had Type 2 diabetes for three years, but did not disclose this until the signing. Meanwhile, she was promoting dishes that can worsen diabetes. This caused a debate about whether Novo Nordisk was cynical and hypocritical for choosing Deen to promote its medicines

    These are all directly from investor websites, not from Novo or Amylin. Now There's the unbiased truth.
     
  6. Anonymous

    Anonymous Guest

    These are all directly from investor websites, not from Novo or Amylin. Now There's the unbiased truth.[/QUOTE]

    The truth will be evident in about 6 months when the launch is a failure.
    just wait
     
  7. Anonymous

    Anonymous Guest

    The truth will be evident in about 6 months when the launch is a failure.
    just wait[/QUOTE]


    You're on. Let's meet back here in 6 months. It won't be a blockbuster in just 6 months but I assure you the launch will not be a failure. I think you will find, as we do, it will be harder for Novo to maintain growth and ward off Bydureon intrusion and Amylin will see that it will not be a piece of cake to grow and capture the market. Time will tell. I'm placing my flag on the Bydureon team. People much smarter than you or I suggest the same.
     
  8. Anonymous

    Anonymous Guest


    You're on. Let's meet back here in 6 months. It won't be a blockbuster in just 6 months but I assure you the launch will not be a failure. I think you will find, as we do, it will be harder for Novo to maintain growth and ward off Bydureon intrusion and Amylin will see that it will not be a piece of cake to grow and capture the market. Time will tell. I'm placing my flag on the Bydureon team. People much smarter than you or I suggest the same.[/QUOTE]

    The trajectory of the first 6 months set the stage for succes of the company.

    what do you think the attrition rate will be?

    The peeps were happy today becasue of the booze, but will sober up by Sunday because nothing has changed at the big A. Crap a$$ salary, no advancement, $hitload of work $tupid Exec management.
     
  9. Anonymous

    Anonymous Guest

    The reality is that Bydureon will destroy Victoza market share. This is almost certain.

    The trouble for Bydureon will come with growing the class market once the low hanging fruit of Victoza has been gobbled up.
     
  10. Anonymous

    Anonymous Guest

    When people say they can't think strategically, this is a great example of it. The point is you can only get your simple mind around the current injection. However, a strategic person would say that the FDA has approved the molecule which paves the way for future enhancements. You must have worked for RIM or Kodak, right?
     
  11. Anonymous

    Anonymous Guest

    Nice post! Like the comparisons at the end.

    I wanted to ask those fuck sticks from novo how much volume does levemir do annually? Been out for over 5 years is it a blockbuster? All you assholes selling it for the past 5+years certainly a blockbuster drug right? I mean you novo d-bags think you know everything there is to know about diabetes, think you outsell everyone, and certainly have a large presence in the market...what are your annual sales for Levemir?

    Your only blockbuster is novolog, and you barely promote it.

    Can't wait to own the glp-1 space again. Can't wait to cash in on the 5k shares of AMLN I bought 2 weeks ago for $10 now over $15.
     
  12. Anonymous

    Anonymous Guest

    DURATION 6 mothafkas
     
  13. Anonymous

    Anonymous Guest

    You really need to get a life loser. Go post more negative thoughts somewhere else.
     
  14. Anonymous

    Anonymous Guest

    Levemir has been selling over MAT $1bn annually worldwide for about 18 months now, so yes it is a blockbuster.

    It would actually be worth a look more closely at how NN acheived this as at launch levemir had inferior data, the wrong european license (BB only for a while 2yrs pre US launch) and was launching against a highly dominant and aggressively marketed competitor (insulin glargine). The fact is that where it was skillfully marketed at niche potions of the basal market, it performed very well, (type 1s, paeds, BBolus) where it tried to go mano a mano with glargine od in type 2 insulin starts it flopped.

    A similarly targeted approach with Bydureon might be the way to go.
     
  15. Anonymous

    Anonymous Guest

    Even as an unabashed NN fan, I find the Paula Deen link embarrassing, counterproductive and downright shameful.

    Even if it works and makes tons of $$$$ the person responsible at NN must see what a hypocritical situation it puts us in.
     
  16. Anonymous

    Anonymous Guest

    Ask Paris Hilton - any publicity is good publicity. Drugs with boxed warnings can't be advertised folks. This Paula Deen controversy has Victoza all over the place including her cover story in people magazine which most of the female diabetic population probably reads each week. Who cares when she did or did not tell that she had diabetes. She already looks much thinner and you can bet people will start asking their doctors about this Victoza stuff.
     
  17. Anonymous

    Anonymous Guest

    what denomination is MAT? It took Levemir 4 years to reach your number. Let's see what happens with Bydureon in that amount of time in a similiar competitive environment.
     
  18. Anonymous

    Anonymous Guest

    23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23--23
     
  19. Anonymous

    Anonymous Guest

    Novo troll go back to your hole. You must have no life what so ever. I feel sorry that you waste your time posting here.
     
  20. Anonymous

    Anonymous Guest

    The real question is: are insurance companies going to call it a 'line extension' or a new drug?
    If they place it as a new drug, then no one will approve it....and there goes sales :(
    Can anyone answer this question????????